COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,015 Articles (22,627 medRxiv, 8,388 bioRxiv)

Most recent first Previous |  Page 398: Articles 3971-3980  | Next

Understanding COVID-19 Vaccine Uptake and Hesitancy Among People With HIV in Freetown, Sierra Leone: A Cross-sectional Study
Cummings, P. E., Lakoh, S., Yendewa, S. A., Massaquoi, S. P. E., James, P. B., Sahr, F., Deen, G. F., Gevao, P., Yendewa, G. A.
10.1101/2023.05.11.23289882 — Posted: 2023-05-16
Heterogeneous changes in mobility in response to the SARS-CoV-2 Omicron BA.2 outbreak in Shanghai
Zhang, J., Tan, S., Peng, C., Xu, X., Wang, M., Lu, W., Wu, Y., Sai, B., Cai, M., Kummer, A. G., Chen, Z., Zou, J., Li, W., Zheng, W., Liang, Y., Zhao, Y., Vespignani, A., Ajelli, M., Lu, X., Yu, H.
10.1101/2023.05.12.23289890 — Posted: 2023-05-16
A synthetic delivery vector for mucosal vaccination
Billet, A., Hadjerci, J., Tran, T., Kessler, P., Ulmer, J., Mourier, G., Ghazarian, M., Gonzalez, A., Thai, R., Urquia, P., Vanbaelen, A.-C., Meola, A., Fernandez, I., Deville-Foillard, S., MacDonald, E., Paolini, L., Schmidt, F., Rey, F. A., Kay, M. S., Tartour, E., Servent, D., Johannes, L.
10.1101/2023.05.15.540756 — Posted: 2023-05-16
Mechanism Underlying the Immune Responses of a Sublingual Vaccine for SARS-CoV-2 with RBD Antigen and Adjuvant, Poly(I:C) or AddaS03, in Non-human Primates
Yamamoto, T., Mitsunaga, F., Wasaki, K., Kotani, A., Tajima, K., Tanji, M., Nakamura, S.
10.1101/2023.05.15.540684 — Posted: 2023-05-16
Defining distinct RNA-protein interactomes of SARS-CoV-2 genomic and subgenomic RNAs
Whitworth, I. T., Knoener, R., Puray Chavez, M., Halfmann, P., Romero, S., Baddouh, M., Scalf, M., Kawaoka, Y., Kutluay, S. B., Smith, L. M., Sherer, N. M.
10.1101/2023.05.15.540806 — Posted: 2023-05-16
Metformin an anti-diabetic drug, possess ACE-2 receptor-SARS- Cov-2 RBD binding antagonist activity, anti-inflammatory and cytokine inhibitory properties suitable for treatment of COVID-19
Saxena, U., Meher, K., K, S., Vangala, S.
10.1101/2023.05.14.540726 — Posted: 2023-05-15
A peptide derived from the SARS-CoV-2 S2-protein heptad-repeat-2 inhibits pseudoviral fusion at micromolar concentrations: Role of palmitic acid conjugation
Düzgünes, N., Tao, Z., Zhang, Y., Krajewski, K.
10.1101/2023.05.13.540576 — Posted: 2023-05-15
Immune response to SARS CoV2 infection by TLR3, TLR4 and TLR7 expression
Martinez Marignac, V. L., Oertlin, G. S., Favant, J. L., Fleishmann, E., Salinas, M., Marchetti, G., Gazali, Z., Richard, S. M.
10.1101/2023.05.12.23288889 — Posted: 2023-05-14
Ability to detect fake news predicts sub-national variation in COVID-19 vaccine uptake across the UK
Loomba, S., Maertens, R., Roozenbeek, J., Götz, F. M., van der Linden, S., de Figueiredo, A.
10.1101/2023.05.10.23289764 — Posted: 2023-05-14
Effectiveness of drugs for COVID-19 inpatients in Japanese medical claim data as average treatment effects with inverse probability weighted regression adjustment
Mitsushima, S., Horiguchi, H., Taniguchi, K.
10.1101/2023.05.12.23289913 — Posted: 2023-05-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).